Sacral Nerve Stimulation Market Expected to Reach $702.1 Million by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Sacral Nerve Stimulation Market," The sacral nerve stimulation market share was valued at $422.66 million in 2022, and is estimated to reach $702.1 million by 2032, growing at a CAGR of 5.2% from 2023 to 2032.

Sacral nerve stimulation is a medical procedure that involves implantation of a device to deliver electrical stimulation to the sacral nerves, which play a crucial role in controlling bladder and bowel function. The device, typically a small neurostimulator, is implanted under the skin and connected to electrodes placed near the sacral nerves. By delivering controlled electrical impulses, sacral nerve stimulation helps regulate nerve activity, modulate bladder and bowel function, and improve symptoms associated with conditions such as urinary and fecal incontinence. This therapeutic approach aims to restore normal control and enhance quality of life for individuals affected by these conditions.

The major factors that contribute to the growth of the sacral nerve stimulation market size include surge in technological advancements in sacral nerve stimulation industry, rise in prevalence of urological incontinence and overactive bladder, and availability of medical reimbursements for sacral nerve stimulation procedure. One of the most significant advancements in sacral nerve stimulation industry is the development of rechargeable batteries. Traditional sacral nerve stimulation devices require replacement of the battery every few years, which can be costly and require surgery. Rechargeable sacral nerve stimulation devices, on the other hand, can be charged using a wireless charger and can last for several years. This makes sacral nerve stimulation devices more convenient for patients and reduces the need for frequent battery replacements. For instance, Axonics, Inc., a global medical technology company that develops and commercialize novel products for the treatment of bladder and bowel dysfunction, offers wireless charging system for its AxonicsR20 implant. Thus, availability of rechargeable sacral nerve stimulation system boosts the growth of the sacral nerve stimulation market trends .

In addition, advancements such as miniaturized implantable devices, advanced programming capabilities, and improved electrode designs have enhanced the precision and customization of therapy, thus driving the market growth. These advancements allow for better targeting of specific nerve fibers and more effective modulation of nerve activity, resulting in enhanced symptom control and reduced side effects.

Furthermore, rise in the number of people affected by overactive bladder is a significant factor contributing to the growth of the sacral nerve stimulation market forecast period. Overactive bladder is a common condition that affects a substantial portion of the population. For instance, according to a report by the Cleveland Clinic in 2022, up to 33 million adults in the U.S. experience symptoms of overactive bladder, with prevalence rates of around 30% in men and 40% in women. The prevalence of overactive bladder is particularly high in women.

The demand for sacral nerve stimulation as a viable treatment option is expected to grow with rise in prevalence of overactive bladder. The ability of sacral nerve stimulation to improve symptoms and enhance quality of life makes it an attractive choice for individuals struggling with overactive bladder. Consequently, this drives the growth of the sacral nerve stimulation market.

Furthermore, the growth of the sacral nerve stimulation market is majorly driven by increase in awareness and acceptance of sacral nerve stimulation therapy among patients and healthcare providers. The effectiveness of sacral nerve stimulation devices has been well-established in clinical trials and studies, and many patients who have failed to find relief with other traditional treatments are turning to sacral nerve stimulation therapy, which propels the market expansion. In addition, the patient can use a handheld controller to adjust the settings of the sacral nerve stimulation device. 

The patient can increase or decrease the intensity of the electrical impulses as well as change the frequency and duration of the impulses. This allows the patient to customize the therapy according to their ,own needs and preferences. Moreover, surge in adoption of sacral nerve stimulation devices by healthcare has contributes to the growth of the market. Physicians are increasingly recognizing the benefits of sacral nerve stimulation and are recommending it as a treatment option for patients who have not responded to other forms of therapy. Thus, increase in awareness of sacral nerve stimulation among physicians and patients is expected to drive the market growth during the forecast period. 

On the basis of product, the market is categorized into devices and accessories. The devices segment accounted for largest share in 2022 and is expected to register the highest CAGR during the forecast period, owing to availability of sacral nerve stimulation devices, and rise in reserch and development activities focusing on advancing the stimulators. In addition, increasing adoption of sacral nerve stimulation devices by healthcare professionals further drives the market growth. 

Depending on application, the market is fragmented into urinary fecal incontinence, chronic anal fissure, and others. The others segment includes overactive bladder syndrome and urinary frequency. The urinary fecal incontinence segment accounted for largest share in terms of revenue in 2022 and is expected to register the highest CAGR during the forecast period, owing to increasing prevalence of conditions such as obstetric trauma, voiding dysfunction, interstitial cystitis, and fecal impaction. These conditions lead to disruptions in bladder and bowel control, resulting in urinary and fecal incontinence. Thus, demanding targeted approach to address the underlying nerve dysfunction associated with these conditions. In addition, the growing focus of the key players in development of stimulators for wide application drives the segment growth. However, chronic anal fissure segment is projected to manifest the highest sacral nerve stimulation market share in CAGR of 9.9% from 2023 to 2032, owing to an increasing awareness of this condition, advancements in medical diagnostics, and the growing adoption of sacral nerve stimulation as an effective therapeutic approach for managing chronic anal fissures and associated symptoms.

By end user, the market is segregated into hospitals, specialty clinics, and others (research centers, ambulatory surgical centers). The hospitals segment accounted for the largest share in terms of revenue in 2022, and is anticipated to register the highest CAGR during the forecast period, owing to availability and access to specialized healthcare professionals, advanced medical technologies and infrastructure, and strong relationships with insurance providers, thus resulting in adoption of sacral nerve stimulation therapy. However, Specialty Clinics segment is projected to manifest the highest CAGR of 7.4% from 2023 to 2032, owing to specialized clinical settings offering targeted care and expertise in treating urological incontinence conditions. Patients seeking tailored solutions are likely to opt for these clinics, thereby driving their prominence in the sacral nerve stimulation market analysis.

Region-wise, North America accounted for the largest sacral nerve stimulation market size in terms of revenue in 2022, owing to high prevalence of urological incontinence conditions, availability of advanced healthcare facilities, and presence of major players offering sacral nerve stimulation devices. In addition, favorable reimbursement policies in healthcare systems and rise in geriatric population are expected to propel the market expansion. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in the number of cases of overactive bladder and urinary incontinence conditions, increase in awareness regarding available sacral nerve stimulation treatment devices, and surge in investments for development of effective sacral nerve stimulation devices. Furthermore, upsurge in healthcare expenditure in emerging economies is anticipated to offer lucrative opportunities for market expansion.
 Key findings of the study

• By product type, the devices segment accounted for the largest share in terms of revenue in 2022, and is expected to register the highest CAGR during the forecast period.
• On the basis of application, the urinary fecal incontinence segment was the major shareholder in terms of revenue in 2022 and is expected to register the highest CAGR during the forecast period.
• Depending on end user, the hospitals segment garnered the largest share in terms of revenue in 2022, and is anticipated to register the highest CAGR during the forecast period.
• Region-wise, North America occupied the largest share in terms of revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.